author-photo

Anne E. Borgman-Hagey

Exelixis

7

Papers

831

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Cabozantinib in Hepatocellular Carcinoma.

2018 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (8)
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (71)
4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (716)
742TiPPHASE 3 RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB (CELESTIAL) (NCT01908426)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (11)